Calypte Biomedical To Host Conference Call CEO to Discuss The International AIDS Conference and Recent Clinical Data Disclosed at Event PLEASANTON, Calif., July 21 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC:CYPT) (BULLETIN BOARD: CYPT) , announced today that Dr. Richard George, Calypte's President and Chief Executive Officer, will host a conference call on Thursday morning at 11:00 am EDT to discuss the recently concluded XV International AIDS Conference in Bangkok, Thailand, as well as provide an in-depth discussion of the recently released data from the Thailand field trials on the Company's HIV-1/2 rapid urine, oral fluid and blood tests. Investors in the U.S. and Canada interested in participating in the conference call may dial 800-915-4836 and reference the Calypte Biomedical call. International investors may dial 973-317-5319. A live webcast of the conference call accompanied by a moderator activated slide presentation will be available at http://www.shareholder.com/calypte/medialist.cfm . The webcast will be available until August 5, 2004. A replay of the call will be available through August 5, 2004 by calling 888-203-1112 in the U.S. and Canada and 719-457-0820 for international listeners. The replay confirmation code is 693031. The quarterly investors' call on the results of the second quarter ended June 30, 2004 will be held as a separate call on August 12, 2004. ABOUT CALYPTE BIOMEDICAL: Calypte Biomedical Corporation, headquartered in Pleasanton, California, is a public healthcare company dedicated to the development and commercialization of in vitro diagnostic tests, primarily for the detection of antibodies to Human Immunodeficiency Virus (HIV), and other sexually transmitted and infectious diseases. Calypte's currently marketed laboratory- based tests include an enzyme immunoassay (EIA) HIV-1 antibody screening test and an HIV-1 antibody western blot supplemental test, the only two FDA- approved HIV-1 antibody tests for use on urine samples, as well as an FDA- approved serum HIV-1 antibody western blot supplemental test. Calypte is actively engaged in developing new test products for the rapid detection of HIV and other infectious diseases. Calypte believes that there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in lesser-developed countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other infectious diseases may make important contributions to public health. CONTACT: Dr. Richard George, President and CEO Calypte Biomedical Corp. 925.730.7200 Tim Clemensen Rubinstein Investor Relations 212.843.9337 DATASOURCE: Calypte Biomedical Corporation CONTACT: Dr. Richard George, President and CEO of Calypte Biomedical Corp., +1-925-730-7200, ; or Tim Clemensen, of Rubinstein Investor Relations, +1-212-843-9337, for Calypte Biomedical Corporation Web site: http://www.calypte.com/ http://www.shareholder.com/calypte/medialist.cfm

Copyright